Clinical Trials · NCT03658213
To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.
- Phase
- Phase 3
- Recruitment status
- Withdrawn
- Sponsor
- AstraZeneca
- Enrollment
- 0
- Start date
- Mar 2020
- Locations
- 11 sites, China
- Primary endpoint
- Effective inhibition rate of serum estradiol(E2)